Karina Tin, Author at The Column Group

The Column Group Raises Over $400 Million For Its New Fund, TCG Labs-Soleil

The Column Group launches a novel ‘venture-biotech’ model, creating an integrated ecosystem to exclusively fund, discover, and develop single-asset biologic therapies.

The Column Group Raises Over $400 Million For Its New Fund, TCG Labs-Soleil Read More »

Karina Tin

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update

Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders

Tenaya Therapeutics Announces Pricing of Underwritten Offering

The Column Group Raises Over $400 Million For Its New Fund, TCG Labs-Soleil

Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader

Remix Therapeutics™ Appoints Dominic Reynolds, Ph.D., as Chief Scientific Officer

Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases

Carmot Therapeutics Announces Completion of Acquisition by Roche

Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing